Fuller H B Co (FUL) · Sep 24, 2026 · Earnings

H.B. Fuller beats on EPS as pricing lifts margins despite soft volume

Beat — Adjusted EPS $1.52 vs ~$1.45 consensus

H.B. Fuller’s Q3 profit beat consensus as pricing and restructuring drove record margins, but revenue slightly missed and full-year guidance was largely reaffirmed.

H.B. Fuller is in the middle of a portfolio and efficiency transition: it is using Quantum Leap restructuring to push margins above 20% while moving further into higher-growth medical adhesives through the pending AMS acquisition. AMS shareholder approval was already secured in August, and the company expects the deal to close before year-end.

MetricQ3 FY2026Comparison / expectation
Net revenue$938.2M$892.0M last year; ~$940.4M published consensus
Organic revenue growth4.4%4.4% last year
Adjusted EPS$1.52$1.26 last year; ~$1.45 consensus
Adjusted EBITDA$186.7M$170.6M last year; +9%
Adjusted EBITDA margin19.9%19.1% last year
FY2026 adjusted EBITDA guide$655M–$670MPrior $650M–$675M range
FY2026 adjusted EPS guide$4.70–$4.85Prior $4.60–$4.90 range

The earnings beat came from margin execution, not stronger volume. Adjusted EPS of $1.52 exceeded the roughly $1.45 consensus, while revenue of $938 million was modestly below the roughly $940 million published estimate. Pricing increased revenue 7.4% and more than offset lower volume, producing 4.4% organic growth. 〔0〕 The key business improvement was profitability: adjusted gross margin rose 120 basis points to 33.5%, and adjusted EBITDA margin reached a record 19.9%. 〔1〕

The quarter supports the restructuring story across the portfolio. Adjusted EBITDA grew in all three global business units, with margins improving in Hygiene, Health and Consumable Adhesives, Engineering Adhesives, and Building Adhesive Solutions. That makes the margin progress more credible than a result driven by one isolated segment, although the underlying demand picture remains less impressive because volume was still down low-single digits.

Guidance was effectively reaffirmed, not materially raised. The new full-year EBITDA and EPS ranges are narrower than the prior ranges but have essentially unchanged midpoints, while the revenue outlook remains mid-single-digit reported growth and low-single-digit organic growth. The company also increased its expected foreign-exchange contribution to approximately 2%, which helps reported revenue but does not change the underlying demand signal. This is therefore a modest operating execution win rather than a major reset to the 2026 outlook.

Cash generation improved, but working capital is absorbing cash ahead of the AMS deal. Year-to-date operating cash flow rose 17% to $183 million, while net leverage fell to 3.0x from 3.3x a year earlier. However, working capital increased to 18.5% of annualized revenue, up 150 basis points, as Fuller built inventory for Quantum Leap and supply continuity. 〔2〕

Bottom line: This was a profitability-led beat: pricing and restructuring are working, but volume remains soft and the full-year outlook is largely unchanged. The result modestly strengthens the margin-improvement story while leaving the AMS closing and integration as the next major business test.

What to watch next

AMS acquisition closing, expected before year-end

Original filing on SEC EDGAR

More Fuller H B Co news

H.B. Fuller beats on EPS as pricing lifts margins despite soft volume | FUL Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.